A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004

Kidney International, Supplement

Volumn 67, Issue 94, 2005, Pages

  Li, Philip Kam Tao ^a   Weening, Jan J ^a   Dirks, John ^a   Lui, Sing Leung ^a   Szeto, Cheuk Chun ^a   Tang, Sydney ^a   Atkins, Robert C ^a   Mitch, William E ^a   Chow, Kai Ming ^a   D'Amico, Giuseppe ^a   Freedman, Barry I ^a   Harris, David C ^a   Hooi, Lai Seong ^a   De Jong, Paul E ^a   Kincaid Smith, Priscilla ^a   Lai, Kar Neng ^a   Lee, Evan ^a   Li, Fu Keung ^a   Lin, Shan Yan ^a   Lo, Wai Kei ^a   Mani, M K ^a   Mathew, Timothy ^a   Murakami, Mutsumi ^a   Qian, Jia Qi ^a   Ramirez, Sylvia ^a   Reiser, Thomas ^a   Tomino, Yasuhiko ^a   Tong, Matthew K ^a   Tsang, Wai Kay ^a   Tungsanga, Kriang ^a   Wang, Haiyan ^a   Wong, Andrew K ^a   Wong, Kim Ming ^a   Yang, Wu Chang ^a   De Zeeuw, Dick ^a   Yu, Alex W ^a   Memuzzi, Giuseppe ^a   more..

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Consensus statements; ISN; Prevention; Renal disease

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ARISTOLOCHIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HERBACEOUS AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ANEMIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONSENSUS; DISEASE COURSE; DRUG CONTRAINDICATION; GLYCEMIC INDEX; HEALTH CARE COST; HONG KONG; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MEDICAL SOCIETY; NEPHROTOXICITY; PATIENT REFERRAL; POLICY; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; SCREENING; CHRONIC KIDNEY FAILURE; CONSENSUS DEVELOPMENT; MASS SCREENING; NEPHROLOGY; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DIET RESTRICTION; EATING HABIT; ELECTROCARDIOGRAM; ETHNOLOGY; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE POLICY; HYPERTENSION; INTERNATIONAL COOPERATION; KIDNEY DISEASE; METABOLIC DISORDER; POPULATION RESEARCH; RISK FACTOR; SMOKING; URIC ACID BLOOD LEVEL;

HONG KONG; HUMANS; KIDNEY FAILURE, CHRONIC; MASS SCREENING; NEPHROLOGY; SOCIETIES, MEDICAL;

EID: 20144388846     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. LYSAGHT MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13:837-40, 2002
2. GARG AX, KIBERD BA, CLARK WF, et al: Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III: Kidney Int 61:2165-2175, 2002
3. RAMIREZ SP, HSU SI, MCCLELLAN W: Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program. Kidney Int 83:S61-65, 2003
4. CHADBAN SJ, BRIGANTI EM, KERR PG, et al: Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 14:S131-138, 2003
5. ISEKI K, ISEKI C, IKEMIYA Y, FUKIYAMA K: Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 49:800-805, 1996
6. HILLEGE HL, JANSSEN WM, BAK AA, et al Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249:519-526, 2001
7. LI PK, KWAN BC, LEUNG CB, et al, FOR THE HONG KONG SOCIETY OF NEPHROLOGY: Prevalence of silent kidney disease in Hong Kong: The Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. Kidney Int 67 (Suppl 94):S36-40, 2005
8. BOULWARE LE, JAAR BG, TARVER-CARR ME, et al Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 290:3101-3114, 2003
9. KLAG MJ, WHELTON PK, RANDALL BL, et al End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 277:1293-1298, 1997
10. RAMIREZ SP, MCCLELLAN W, PORT FK, HSU SI: Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol 13:1907-1917, 2002
11. SATKO SG, FREEDMAN BI: The importance of family history on the development of renal disease. Curr Opin Nephrol Hypertens 13:337-341, 2004
12. FREEDMAN BI, SOUCIE JM, MCCLELLAN WM: Family history of endstage renal disease among incident dialysis patients. J Am Soc Nephrol 8:1942-1945, 1997
13. AMERICAN DIABETES ASSOCIATION: Clinical practice recommendations 2001. Diabetes Care 24(Suppl 1):S69-S72, 2001
14. KEANE WF, EKNOYAN G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33:1004-1010, 1999
15. DAVIDSON MB, SMILEY JF: Relationship between dipstick positive proteinuria and albumin: creatinine ratios. J Diabetes Complications 13:52-55, 1999
16. GRIMM RH, SVENDSEN KH, KASISKE B, et al, FOR THE MRFIT RESEARCH GROUP: Proteinuria is a risk factor for mortality over 10 years of follow-up. Kidney Int 52(Suppl 63):S10-S14, 1997
17. ANONYMOUS: KDOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39:S1-S246, 2002
18. CORESH J, ASTOR BC, MCQUILLAN G, et al: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39:920-929, 2002
19. LEVEY AS, CORESH J, BALK E, et al: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139:137-147, 2003
20. SHEMESH O, GOLBETZ H, KRISS JP, MYERS BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28:830-838, 1985
21. LEVEY AS, BOSCH JP, LEWIS JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130:461-470, 1999
22. COCKROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
23. SCHWAB SJ, CHRISTENSEN RL, DOUGHERTY K, KLAHR S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 147:943-944, 1987
24. LEVEY AS, BETO JA, CORONADO BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
25. SARNAK MJ, LEVEY AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35:117-131, 2000
26. MANJUNATH G, TIGHIOUART H, CORESH J, et al: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121-1129, 2003
27. HOSTETTER TH: Prevention of the development and progression of renal disease. J Am Soc Nephrol 14(Suppl 2):S144-S147, 2003
28. CHOBANIAN AV, BAKRIS GL, BLACK HR, et al: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 289:2560-2572, 2003
29. EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053, 2003
30. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 45(Suppl 1):S1-S268, 2004
31. GISEN: Randomized placebo-controlled trial effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
32. DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes. N Engl J Med 329:977-986, 1993
33. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837-853, 1998
34. AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes. Diabetes Care 27(Suppl 1):S15-S35, 2004
35. AMERICAN DIABETES ASSOCIATION: Nephropathy in diabetes. Diabetes Care 27(Suppl 1):S79-S83, 2004
36. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
37. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
38. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, et al: Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
39. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
40. KLAHR S, LEVEY AS, BECK GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
41. KASISKE BL, LAKATUA JD, MA JZ, LOUIS TA: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31:954-961, 1998
42. MITCH WE, REMUZZI G: Diets for patients with chronic kidney disease, still worth prescribing. J Am Soc Nephrol 15:234-237, 2004
43. MASUD T, MANATUNGA A, COTSONIS G, MITCH WE: The precision of estimating protein intake in patients with chronic renal failure. Kidney Int 62:1750-1756, 2002
44. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 41(Suppl 3):S1-S70, 2003
45. WHELTON A, HAMILTON CW: Nonsteroidal anti-inflammatory drugs: Effects on kidney function. J Clin Pharmacol 31:588-598, 1991
46. RUDNICK MR, BERNS JS, COHEN RM, GOLDFARB S: Nephrotoxic risks of renal angiography: Contrast media-associated nephrotoxicity and atheroembolism - A critical review. Am J Kidney Dis 24:713-727, 1994
47. OBRADOR GT, PEREIRA BJ: Early referral to the nephrologists and timely initiation of renal replacement therapy: A paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis 31:398-417, 1998
48. ROSSERT J, FOUQUERAY B, BOFFA JJ: Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 14(Suppl 2):S173-S177, 2003
49. EKNOYAN G, LEVIN A, LEVIN NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S201, 2003